Results 181 to 190 of about 1,783,252 (315)
ABSTRACT Background High‐altitude populations typically exhibit elevated hemoglobin (Hb) levels due to chronic hypoxic exposure; however, the impact of this elevation on the risk of ST‐segment elevation myocardial infarction (STEMI) remains unclear. Existing evidence is primarily derived from low‐altitude populations and cannot be directly extrapolated
Jing Li +10 more
wiley +1 more source
Changes in body composition and their association with erythrocyte mass in regular exercisers: A cross-sectional study. [PDF]
Demircioğlu S +4 more
europepmc +1 more source
Hemoglobin Variants in Patients With Microcytic Hypochromic Anemia: A Review of Indian Studies. [PDF]
Kharche K, Bhake A.
europepmc +1 more source
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich +5 more
wiley +1 more source
Haemoglobin variants in nigeria: real-world data from a point-of-care device. [PDF]
Kotila T +8 more
europepmc +1 more source
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Weizhe Jian +7 more
wiley +1 more source
Clinical and hematological characteristics of beta-plus thalassemia and uncommon beta-chain hemoglobin variants in Northern Thailand. [PDF]
Rukwong P +7 more
europepmc +1 more source
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials.
Marella Cornelia Elizabeth van Ruissen +10 more
wiley +1 more source

